Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Region, And Segment - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

The global oncology clinical trials market size reached USD 13.19 billion in 2023 and is projected to hit around USD 22.11 billion by 2033, expanding at a CAGR of 5.3% during the forecast period from 2024 to 2033.

Oncology Clinical Trials Market Size, 2024 to 2033

Key Takeaways:

  • North America dominated the market and accounted for the largest revenue share of 43% in 2023
  • Asia Pacific is expected to grow at the fastest CAGR of 7.1% during the forecast period.
  • Based on type, the market is segmented into phase I, phase II, phase III, and phase IV. The phase I clinical trials segment accounted for the largest revenue share of over 32.0% in 2023.
  • The phase III segment is estimated to register the fastest CAGR of 5.7% over the forecast period.
  • Based on study design, the interventional studies segment accounted for the largest revenue share of around 88.9% in 2023.
  • The observational studies segment is estimated to register the fastest CAGR of 6.2% over the forecast period.

Oncology Clinical Trials Market Growth

The market is primarily driven by factors such as an increase in technological advancements, a rise in cancer incidences, and improvements in personalized medicine and cell and gene therapies, which are starting new approaches for developing new treatments for cancer-like diseases. Moreover, an increase in funding from pharmaceutical and biotech companies, non-profit organizations, and CROs for oncology clinical trials is further supporting market growth and the development of advanced products to gain substantial market share.

The global market is driven by the rising number of cancer patients. Lung cancer is predicted to emerge as the leading cause of cancer-related deaths worldwide, with an estimated 1.8 million people diagnosed each year. The number of cancer cases in the U.S. reached 1.9 million in 2022. In addition, pancreatic cancer has a terrible prognosis, with just 1 to 3 years of survival. The market is expected to be hindered by factors such as cultural and social challenges associated with clinical trial participation, recruitment barriers in the clinical trial process, lack of scientific knowledge, misuse of statistics and data, and complexity of study protocol, whereas mostly the study is funded and organized by the federal government.

The National Center for Biomedical Imaging (NCI) funds approximately 50% of all cancer clinical trials in the U.S., according to Mooney's description of the National Center for Biomedical Imaging Clinical Trials Cooperative Group Program. However, the COVID-19 pandemic slowed down clinical trials of oncology. Many clinical trials were postponed or delayed due to safety concerns and difficulties in recruiting participants during the pandemic.

Oncology Clinical Trials Market Report Scope

Report Attribute Details
Market Size in 2024 USD 13.89 Billion
Market Size by 2033 USD 22.11 Billion
Growth Rate From 2024 to 2033 CAGR of 5.3%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Phase type, study design, region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled AstraZeneca; Merck & Co. Inc.; IQVIA Inc.; Gilead Sciences, Inc.;F. Hoffmann-La Roche Ltd.; PRA Health Sciences; Syneos Health; Medpace; Novotech; Parexel International Corporation

 

Segments Insights:

Phase Type Insights

Based on type, the market is segmented into phase I, phase II, phase III, and phase IV. The phase I clinical trials segment accounted for the largest revenue share of over 32.0% in 2023. The phase I clinical trial segment in the oncology clinical trials industry is driven by scientific, regulatory, financial, and patient-centric factors. In phase I of clinical trials, a small group of individuals (20 to 100 healthy volunteers) undergoes testing with an experimental drug or treatment.

The phase III segment is estimated to register the fastest CAGR of 5.7% over the forecast period. The driving factors for the phase III segment include the high share of phase III trials, which is attributed to the fact that phase III trials are the most expensive but involve many subjects. Long-term safety studies are conducted for registration and post-marketing commitments in phase III trials. For instance, in Jul 2020, a phase III clinical trial of alpelisib in the mix with pertuzumab and trastuzumab was started by Novartis AG to assess the well-being and viability of use as a support therapy for patients with HER2-positive advanced breast cancer.

Study Design Insights

Based on study design, the interventional studies segment accounted for the largest revenue share of around 88.9% in 2023. The driving factors for interventional study design in the oncology clinical trials sector primarily revolve around these conditions' unique challenges. Given the limited patient populations, studies must be meticulously designed to maximize the chances of detecting meaningful treatment effects.

The observational studies segment is estimated to register the fastest CAGR of 6.2% over the forecast period. Due to several driving factors, observational trial study designs play a crucial role in the oncology clinical trials industry. The scarcity of patients with oncology makes traditional randomized controlled trials challenging, making observational studies a more feasible option for assessing treatment efficacy and safety.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 43% in 2023 and is expected to maintain its dominance during the forecast period due to various favorable reimbursement policies and the presence of major market players in the region, leading to investment and the development of innovative products. Also, the U.S. FDA has a fast-track approval process for drugs that treat cancer. For instance, according to the U.S. Government Accountability Office, the National Institutes of Health (NIH), an agency under the Department of Health and Human Services (HHS), stands as the foremost public financier of biomedical research and development (R&D).

During the fiscal years 2018 to 2022, NIH allocated a staggering USD 99 billion for fundamental research and USD 30 billion for clinical trials and associated endeavors. Whereas, Asia Pacific is expected to grow at the fastest CAGR of 7.1% during the forecast period. This is due to the availability of a significant number of Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA), and European Medicines Agency (EMA)-approved facilities in the region. Moreover, the large patient pool and low cost of conducting clinical trials in the region further support the regional market.

Oncology Clinical Trials Market Recent Developments

  • In June 2022, Novartis reported positive outcomes from the Phase III RATIONALE 306 trial, revealing that tislelizumab in combination with chemotherapy significantly enhanced overall survival (OS) as a primary treatment for adult patients dealing with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC), irrespective of their PD-L1 status.
  • In March 2021, Merck Sharp & Dohme Corp. initiated a phase II clinical study to assess the safety and efficacy of the fixed-dose co-formulated pembrolizumab/quavonlimab (MK-1308A) in conjunction with lenvatinib for patients with hepatocellular carcinoma (HCC).

Some of the prominent players in the Oncology Clinical Trials Market include:

  • Astrazeneca
  • Merck & Co., Inc
  • IQVIA Inc
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • PAREXEL International Corporation
  • PRA Health Sciences
  • Syneos Health
  • Medpace
  • Novotech
  • Pivotal

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Oncology Clinical Trials market.

By Phase Type 

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design 

  • Interventional Studies
  • Observational Studies
  • Expanded Access Studies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global oncology clinical trials market size reached USD 13.19 billion in 2023 and is projected to hit around USD 22.11 billion by 2033

The global carbon footprint management market is expected to be driven by increasing concerns regarding the detrimental effects of carbon emissions.

Wolters Kluwer, IBM Corporation, Schneider Electric, and Dakota Software are some of the key companies operating in the carbon footprint management market.

The global oncology clinical trials market will register growth rate of 5.3% between 2024 and 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oncology Clinical Trials Market 

5.1. COVID-19 Landscape: Oncology Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oncology Clinical Trials Market, By Phase Type

8.1. Oncology Clinical Trials Market, by Phase Type, 2024-2033

8.1.1. Phase I

8.1.1.1. Market Revenue and Forecast (2020-2033)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2020-2033)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2020-2033)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Forecast (2020-2033)

Chapter 9. Global Oncology Clinical Trials Market, By Study Design

9.1. Oncology Clinical Trials Market, by Study Design, 2024-2033

9.1.1. Interventional Studies

9.1.1.1. Market Revenue and Forecast (2020-2033)

9.1.2. Observational Studies

9.1.2.1. Market Revenue and Forecast (2020-2033)

9.1.3. Expanded Access Studies

9.1.3.1. Market Revenue and Forecast (2020-2033)

Chapter 10. Global Oncology Clinical Trials Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.1.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.1.3.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.1.4.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.2.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.2.3.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.2.4.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.2.5.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.2.6.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.3.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.3.3.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.3.4.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.3.5.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.3.6.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.4.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.4.3.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.4.4.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.4.5.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.4.6.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.5.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.5.3.2. Market Revenue and Forecast, by Study Design (2020-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Phase Type (2020-2033)

10.5.4.2. Market Revenue and Forecast, by Study Design (2020-2033)

Chapter 11. Company Profiles

11.1. Novartis

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Merck & Co.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Pfizer Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Roche

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Bristol Myers Squibb

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. AstraZeneca

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Johnson & Johnson

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Eli Lilly and Company

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. GlaxoSmithKline

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Sanofi

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers